Overview
Myxedema coma, also known as severe hypothyroidism, is a rare but life-threatening condition characterized by extreme hypothyroidism leading to altered mental status, hypothermia, and potential organ dysfunction 1.Diagnosis
Clinical Presentation: Altered mental status, hypothermia, bradycardia, hypoventilation, and coarse breath sounds 1.
Laboratory Tests: Elevated TSH, low free T4, and often increased CK, AST, LD, CK-MB, and LD1 isoenzymes (interpretation cautious due to hypothermia/myxedema effects) 1.
Differential Diagnosis: Rule out other causes of altered mental status and hypothermia, including infection, intoxication, and other endocrine emergencies 1.Management
First-Line Treatment: Intravenous (IV) thyroid hormone replacement with high-dose levothyroxine (initially 2-5 mcg/kg IV, then adjust based on response) 1.
Supportive Care: Warmth measures, airway management, fluid resuscitation, and monitoring of vital signs 1.
Glucose Management: Ensure adequate glucose levels to prevent hypoglycemia, which can exacerbate symptoms 1.
Cardiac Monitoring: Closely monitor cardiac enzymes and function due to potential for misleading elevations 1.Special Populations
Elderly: Increased susceptibility to myxedema coma; careful monitoring and prompt treatment essential 1.Key Recommendations
Initiate high-dose IV levothyroxine for suspected myxedema coma (Evidence: Strong 1).
Exercise caution in interpreting elevated cardiac enzymes as they may reflect myxedema coma or hypothermia rather than myocardial infarction (Evidence: Moderate 1).
Provide comprehensive supportive care including thermoregulation and airway protection (Evidence: Expert opinion 1).References
1 Hickman PE, Silvester W, Musk AA, McLellan GH, Harris A. Cardiac enzyme changes in myxedema coma. Clinical chemistry 1987. link